Please complete this form relating to your transactions for Athira Pharma, Inc. (NASDAQ: ATHA) common stock: (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Athira’s September 2020 initial public offering (“IPO”); and/or (b) between September 18, 2020 and June 17, 2021, inclusive (the “Class Period”).
You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at firstname.lastname@example.org, or you may click here to print a PDF of this form.
Athira is a late-stage clinical biopharmaceutical company that focuses on developing small molecules to restore neuronal health and stop neurodegeneration. On September 18, 2020, Athira filed its prospectus on a Form 424B4, which forms part of the Registration Statement. In the IPO, Athira sold approximately 13,397,712 shares of common stock at a price of $17.00 per share. Athira received proceeds of approximately $208.5 million from the IPO, net of underwriting discounts and commissions.
According to the complaints, on June 17, 2021, after the market closed, Athira announced in a press release that it had placed its president and Chief Executive Officer, Dr. Leen Kawas, on leave pending a review of actions stemming from doctoral research she conducted while at Washington State University (“WSU”). According to Athira’s press release, Athira’s Board “formed an independent special committee to undertake this review.”
The same day, the scientific publication STAT published an article stating that WSU was investigating claims that Dr. Kawas “published several papers containing altered images while she was a graduate student.” These papers “are foundational to Athira’s efforts to treat Alzheimer’s” because they “established that a particular molecule affects the activity of HGF.” Though Athira is developing a different molecule than the one Dr. Kawas examined in the papers at issue, her “doctoral work laid the biological groundwork that Athira continues to use in their approach to treating Alzheimer’s.” Specifically, “[i]mages of Western blots, used to determine the presence of specific proteins in biological samples, look as though they’ve been altered from their original state.” According to experts cited in the article, “If the Western blots are inaccurate, then the whole study must be redone.”
Following this news, Athira’s share price fell $7.09, or approximately 39%, to close at $11.15 per share on June 18, 2021.
The complaints allege that in the Registration Statement and/or throughout the Class Period the defendants made materially false and misleading statements and omitted to state that: (1) Dr. Kawas had published research papers containing improperly altered images while she was a graduate student; (2) this purported research was foundational to Athira’s efforts to develop treatments for Alzheimer’s because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer’s; (3) as a result, Athira’s intellectual property and product development for the treatment of Alzheimer’s was based on invalid research; and (4) as a result of the foregoing, the defendants’ positive statements about Athira’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at email@example.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.